Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR444881 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Biond Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SAR444881 + pembrolizumab is an investigational drug combination intended for use in patients with advanced or metastatic solid tumors. SAR444881 is a monoclonal antibody targeting the immune inhibitory receptor LILRB1 (also called ILT2), and is designed to block immunosuppressive signals on immune cells, thereby enhancing the immune-mediated anti-tumor response. Pembrolizumab is a well-established immune checkpoint inhibitor, specifically a monoclonal antibody targeting PD-1 (programmed cell death protein 1) on T lymphocytes, preventing the interaction with its ligand PD-L1 and restoring T-cell mediated anti-tumor immunity. This combination is currently in clinical trials for efficacy and safety in solid tumors, including but not limited to non-small cell lung cancer, gastric/gastroesophageal cancer, and colorectal cancer. The primary sponsor and developer for the combination trial is Sanofi.
- Brand names
- Keytruda
- Other names
- SAR444881 + pembrolizumab
02
Targets
LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SAR444881 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR444881 + pembrolizumab.